SenzaGen AB 2025 AR2
The report highlights SenzaGen's progress in 2025, including a 1% increase in net sales to SEK 58.0 million and an 8% increase in GARD® sales to SEK 41.9 million. The company achieved a major regulatory milestone with the inclusion of GARD®skin in the OECD Test Guideline 497, strengthening its position in non-animal regulatory testing. SenzaGen also presented its 2030 Growth Plan, expanded its laboratory facilities in Lund, and introduced EpiSensA as a complementary skin sensitization test. Additionally, the company maintained its commitment to sustainability, aligning its operations with the UN Global Compact and key Sustainable Development Goals.
Company: SenzaGen AB
Sector: Professional & technical services
Country: Sweden
Year: 2025
Type: AR2
Pages: 90
Back to company
SenzaGen AB
Annual Report
The report highlights SenzaGen's progress in 2025, including a 1% increase in net sales to SEK 58.0 million and an 8% increase in GARD® sales to SEK 41.9 million. The company achieved a major regulatory milestone with the inclusion of GARD®skin in the OECD Test Guideline 497, strengthening its position in non-animal regulatory testing. SenzaGen also presented its 2030 Growth Plan, expanded its laboratory facilities in Lund, and introduced EpiSensA as a complementary skin sensitization test. Additionally, the company maintained its commitment to sustainability, aligning its operations with the UN Global Compact and key Sustainable Development Goals.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees